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and colleagues. Five pharmaceutical industry–funded 
laboratories across Canada were included in a validation 
and quality control exercise for the EGFR test. Patients with 
nonsquamous lung cancer were enrolled online, where basic 
demographics and decision on gefinitib prescription were 
recorded. Of the 2104 requests for EGFR mutation testing, 
84% were fulfilled, with a median turnaround time of 18 
days. The majority of the requests were for adenocarcinoma 
and stage IV disease, 58% women, 41% light/never 
smokers, and 13.9% Asians. Among patients tested for 
EGFR mutation, 17% were prescribed with gefitinib. 
The number of tests requested each month dropped from 
200–250 to 50–100 after the initial 12 months, funded 
by pharmaceutical industry. This study indicates that 
funding has a substantial impact on the uptake of EGFR 
test, therefore a national strategy on securing resources to 
implement molecular testing is required. (p. 1136)
•	 Overexpression of EPH 
B2 Receptor in Malignant 
Mesothelioma Correlates 
with Oncogenic Behavior
Expression arrays showed EPHB2 level to be significantly 
up-regulated in MM tumor tissue versus paired normal 
peritoneum. Results from real-time polymerase chain 
reaction and immunoblotting demonstrated overexpression 
of EPHB2 in all MM cell lines, but not in benign 
mesothelial cells. Functional evaluation of EPHB2 in two 
mesothelioma cell lines, HP-1 and H2595, revealed its 
effect on its downstream targets: Knockdown of EPHB2 
decreased expression of MMP-2 and vascular endothelial 
growth factor, and increased expression of Caspases 2 and 
8; a significant decrease in scratch closure, proliferation, and 
invasion as well as significant increase in apoptotic proteins 
and activity were also observed. The findings suggest a role 
of EPHB2 in MM pathogenesis and a potential target for 
therapeutic intervention of MM. (p. 1203)
IN THIS ISSUE
In this study, challenges to the initial implementation of the epidermal 
growth factor receptor (EGFR) mutation test, which is predictive 
of better outcomes from first-line EGFR tyrosine kinase inhibitor 
treatments compared with chemotherapy, were assessed by Ellis 
Goparaju and colleagues investigated the expression of the Ephrin 
B2 receptor (EPHB2) in malignant pleural mesothelioma (MM) cell 
lines and tumors, and its impact on proliferation and invasion of MM. 
•	 Body Mass Index and Its 
Association with Clinical 
Outcomes for Advanced 
Non–Small-Cell Lung 
Cancer Patients Enrolled 
on Eastern Cooperative 
Oncology Group Clinical 
Trials
The authors set out to assess the association of body 
mass index and clinical outcomes in patients with 
advanced non–small-cell lung cancer, who enrolled 
to three consecutive first-line trials of the Eastern 
Cooperative Oncology Group. Overall survival 
(OS), progression-free survival, and reasons for 
terminating treatment were analyzed in this study. 
Of the 2585 patients enrolled, 16.9% were obese, 
34.3% were overweight, 44.1% were normal, and 
4.6% were underweight. After a median follow-up 
of 64.9 months, the findings revealed a median OS 
and a median progression-free survival, respectively, 
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from 0.86 to 1.54 later during the treatment. Taken 
together, the findings indicate an association between 
body mass index and differential clinical outcomes in 
patients with advanced non–small-cell lung cancer. 
Further studies on the mechanisms of this association 
and on interventions through diet and lifestyle control 
are required to improve clinical outcomes in the study 
population. (p. 1121)
•	 Resistance to EGFR-
TKI Can Be Mediated 
through Multiple Signaling 
Pathways Converging 
upon CAP-Dependent 
Translation in EGFR-Wild 
Type NSCLC
before immunoblot detection of EGFR signaling and 
downstream pathway activation. Twenty-four hours 
after erlotinib treatment, serum-repleted cells were 
immunoblotted for EGFR signaling and mediators of 
cap-dependent translation. Effect on cell viability was 
examined when erlotinib was in combination with two 
different cap-dependent translation inhibitors. The 
results demonstrated that in EGFR wild-type cells, 
EGFR signaling is associated with cap-dependent 
translation activation. In erlotinib-resistant cells, 
erlotinib blocks EGFR phosphorylation, but activation 
of Akt and ERK1/2 sustains eIF4F activation and hence 
maintains eIF4F cap-complex, which does not occur 
in erlotinib-sensitive cells. Blocking cap-dependent 
translation also demonstrated increased sensitivity to 
erlotinib. Further studies of combination treatment with 
these translation inhibitors and erlotinib in clinical trials 
are warranted in addressing resistance to EGFR tyrosine 
kinase inhibitor in NSCLC. (p. 1142)
•	 Association of Patterns of 
Subtypes of Exon 19 and 
21 EGFR Mutations with 
Treatment Outcome after 
First-Line Tyrosine Kinase 
Inhibitor in Metastatic 
Non–Small-Cell Lung 
Cancer
in patients with metastatic non–small-cell lung cancer 
(NSCLC) was investigated by Lee and colleagues in 
this study. Of the 452 patients with stage IIIB and IV 
NSCLC, 42.5% had epidermal growth factor receptor 
mutation, and 37.5% were treated with first-line TKI, 
whose survival outcomes were compared between 
subtypes of exon 19 and exon 21 mutations. The results 
demonstrated differential survival to first-line TKI 
treatment with different mutation subtypes: The median 
progression-free survival (PFS) in patients with exon 
19 deletions ranged from 6.5 months (18-nucleotide 
deletion [delL747_P753insS]) to 22.3 months (mixed 
insertion/substitution mutation); those with deletions 
starting on codon E746 had better median PFS (14.2 
months) vs. those on L747 (6.5 months). The median 
PFS in those harboring exon 21 mutations was longer 
in L858R subtype (11.4 months) versus L861R/
L861Q subtype (2.1 months). This study suggests that 
further detailed studies on exon 19 deletions could 
gain important insights in prognosis for TKI therapy in 
metastatic NSCLC patients. (p. 1148)
of 7.0 and 2.7 months for underweight patients, 8.6 and 3.9 
months for those of normal weight, 9.3 and 4.4 months for those 
overweight, and 11.0 and 5.1 months for obese patients. Relative 
to normal/overweight patients, obese patients experienced 
superior outcomes earlier in the treatment. The outcomes in 
obese patients were time dependent: their risk of death from any 
cause increased dramatically once they had been on study longer 
than 16 months, with a significant increase in OS hazard ratio 
On the basis of previous studies on acquired epidermal growth 
factor (EGFR) receptor tyrosine kinase inhibitor resistance that 
showed Akt activation mediates cap-dependent protein translation, 
the authors evaluated a strategy of targeting cap-dependent 
translation in combination with erlotinib in an attempt to improve 
therapy in non–small-cell lung cancer (NSCLC). EGFR wild-
type NSCLC cells were analyzed for erlotinib sensitivity. NSCLC 
cells were serum-starved and subjected to EGF stimulation 
Whether different subtypes of epidermal growth factor receptor 
mutations on exon 19 and exon 21 are associated with different 
survival outcomes to first-line tyrosine kinase inhibitors (TKIs) 
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Tsujino and colleagues conducted a pooled analysis of 
literature (7 phase III and 34 phase II studies) published 
before December 31, 2011 to examine the survival benefit 
of consolidation chemotherapy (CCT) after concurrent 
chemo-radiotherapy in patients with locally advanced 
non–small-cell lung cancer. Median overall survival and 
other clinical data were pooled. Trial arms with CCT 
were designated CCT+ (25 arms) whereas CCT− for 
without CCT (20 arms). The findings showed no statistical 
difference between CCT+ and CCT− in pooled median 
overall survival (19.0 months versus 17.9 months, 
respectively), and in grade 3 to 5 toxicities in pneumonitis, 
esophagitis, and neutropenia. Predicted hazard ratio was 
0.94. The authors concluded that this study, based on pooled 
literature, revealed no significant survival prolongation or 
death risk reduction from the addition of CCT for locally 
advanced non–small-cell lung cancer patients. (p. 1181)
RESEARCH WATCH
•	 Single-Agent Pemetrexed 
versus Carboplatin and 
Pemetrexed in Patients 
with Advanced Non–
Small-Cell Lung Cancer 
and Eastern Cooperative 
Oncology Group 
Performance Status of 2: A 
Randomized Phase III Trial
alone (500 mg/m2) or CP (5 and 500 mg/m2, respectively). This was 
the first study to demonstrate improved survival from combination 
chemotherapy compared with single-agent chemotherapy in patients 
with ECOG PS of 2. The primary endpoint, median overall survival, 
was 5.3 months (P) and 9.3 months (CP). One-year survival rates 
were 21.9% and 40.1%, respectively. The secondary endpoints, 
response rate, and progression-free survival, were also significantly 
improved with CP: 10.3% (P) versus 23.8% (CP), and 2.8 months 
(P) versus 5.8 months (CP), respectively. The findings revealed 
a low and manageable toxicity profile, except for four treatment-
related deaths in the CP arm, which indicates that close monitoring 
of these patients is required. The authors concluded that the study 
strongly suggests CP to be superior to single-agent P, and patients 
with an ECOG PS of 2 should receive the treatment.
Zukin M, Barrios CH, Rodrigues Pereira J, et al. Randomized 
phase III trial of single-agent pemetrexed versus carboplatin and 
pemetrexed in patients with advanced non-small-cell lung cancer 
and Eastern Cooperative Oncology Group performance status of 2. 
J Clin Oncol doi:10.1200/jco.2012.48.1911 (2013).
•	 Is Consolidation 
Chemotherapy after 
Concurrent Chemo-
Radiotherapy Beneficial 
for Patients with Locally 
Advanced Non–Small-Cell 
Lung Cancer? A Pooled 
Analysis of the Literature
A prospective randomized phase III trial was conducted to compare 
single-agent pemetrexed (P) with the combination of carboplatin 
and pemetrexed (CP) in the first-line management of patients with 
advanced non–small-cell lung cancer with an Eastern Cooperative 
Oncology Group (ECOG) performance status (PS) of 2. A total of 
205 patients from Brazil and the United States with nonsquamous 
advanced non–small-cell lung cancer and no prior chemotherapy 
were enrolled from April 2008 to July 2011, and randomized to P 
•	 LUX-Lung 3: Randomized 
Phase III Trial of Afatinib 
or Cisplatin Plus 
Pemetrexed in Patients 
with Metastatic Lung 
Adenocarcinoma with 
EGFR Mutations
evaluated the efficacy of chemotherapy compared with afatinib. 
There were 345 patients with stage IIIB/IV lung adenocarcinoma 
bearing EGFR mutation randomly assigned to 40 mg afatinib 
per day or cisplatin plus pemetrexed chemotherapy at standard 
doses every 21 days. The primary endpoint, median progression-
free survival, of afatinib was 11.1 months versus 6.9 months 
for chemotherapy. Secondary endpoints were tumor response, 
overall survival, adverse events, and patient-reported outcomes. 
Treatment-related side effects were manageable and primarily 
expected from EGFR inhibitors. Improved patient-reported 
outcomes were observed, with better control of lung cancer–
related symptoms. This study demonstrated that afatinib could 
be a standard regimen for patients with advanced lung–positive 
Afatinib is a selective, orally bioavailable inhibitor of ErbB 
family including epidermal growth factor receptor (EGFR/
ErbB1), human epidermal growth factor receptor 2, and ErbB4, 
with preclinical activity in EGFR mutation-positive tumors. Its 
efficacy was also demonstrated in a phase II study of EGFR 
mutation–positive lung adenocarcinoma. The LUX-Lung 3 study 
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•	 FASTACT-2: Intercalated 
Combination of 
Chemotherapy and 
Erlotinib for Patients with 
Advanced Non–Small-Cell 
Lung Cancer
plus placebo. Frequency of serious adverse events was comparable 
between the two groups: 31% in chemotherapy plus erlotinib and 
34% in chemotherapy plus placebo. Neutropenia, thrombocytopenia, 
and anemia were the most common grade 3 or higher adverse events. 
Only patients harboring epidermal growth factor receptor (EGFR) 
activating mutations demonstrated treatment benefits, with median 
PFS of 16.8 months versus 6.9 months, and median overall survival of 
31.4 months versus 20.6 months. But patients with unknown EGFR 
mutation status presented with no detrimental effects. The authors 
concluded that intercalated combination of chemotherapy and erlotinib 
is a potential first-line treatment compared with the standard regimen 
for non–small-cell lung cancer patients with EGFR mutations and 
with unknown EGFR mutation status but showing clinical parameters 
of high EGFR mutation incidence.
Wu Y-L, Lee JS, Thongprasert S, et al. Intercalated combination 
of chemotherapy and erlotinib for patients with advanced stage non-
small-cell lung cancer (FASTACT-2): a randomised, double-blind 
trial. Lancet Oncol 2013;14:777–786.
for EGFR mutations, based on the findings of prolongation of 
progression-free survival, tumor response, and improved lung 
cancer–related symptoms when first-line afatinib treatment was 
used versus cisplatin plus pemetrexed.
Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of 
afatinib or cisplatin plus pemetrexed in patients with metastatic lung 
adenocarcinoma with EGFR mutations. J Clin Oncol doi:10.1200/
jco.2012.44.2806 (2013).
Four hundred and fifty-one patients with stage IIIB/IV non–small-cell 
lung cancer (NSCLC) enrolled in FASTACT-2, a randomized, double-
blind phase 3 trial, and were randomly assigned to receive six cycles of 
gemcitabine plus platinum, intercalated with erlotinib (chemotherapy 
plus erlotinib) or placebo (chemotherapy plus placebo) every 4 
weeks. Primary endpoint was progression-free survival (PFS) in the 
intention-to-treat population. The primary goal was to compare PFS 
of the intercalated combination regimen with standard chemotherapy. 
The findings demonstrated significantly prolonged median PFS 
with chemotherapy plus erlotinib (7.6 months) versus chemotherapy 
plus placebo (6 months); median overall survival of 18.3 months in 
chemotherapy plus erlotinib versus 15.2 months in chemotherapy 
•	 PARAMOUNT Phase III 
Study of Maintenance 
Pemetrexed versus 
Placebo Immediately 
after Induction Treatment 
with Pemetrexed Plus 
Cisplatin for Advanced 
Nonsquamous Non–Small-
Cell Lung Cancer: The Final 
Overall Survival Results
The authors updated data on final overall survival and safety of the 
phase III trial PARAMOUNT in which pemetrexed maintenance 
therapy was shown to lower the risk of disease progression in advanced 
nonsquamous non–small-cell lung cancer versus placebo. Patients with 
Eastern Cooperative Oncology Group performance status 0 or 1, whose 
disease did not progress after four cycles of pemetrexed–cisplatin 
induction therapy, were randomized to maintenance pemetrexed or 
placebo. There were 397 deaths (71% pemetrexed; 78% placebo) after 
a mean of 7.9 maintenance cycles with pemetrexed and five cycles with 
placebo. The remaining patients were followed up for a median of 24.3 
months and demonstrated statistically significant 22% decrease in the 
risk of death from pemetrexed therapy. Median overall survival was 
13.9 months for pemetrexed and 11.0 months for placebo. Improved 
survival was observed consistently in the pemetrexed arm for patients 
with partial/complete response and stable disease after induction 
therapy. Drug-related grade 3/4 adverse events were significantly 
higher in the pemetrexed arm but no new safety events were reported. 
Pemetrexed maintenance therapy is well-tolerated and exhibits 
superior survival in the study population, showing that it is an effective 
treatment option for these patients.
Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: 
final overall survival results of the phase III study of maintenance 
pemetrexed versus placebo immediately after induction treatment 
with pemetrexed plus cisplatin for advanced nonsquamous non-small-
cell lung cancer. J Clin Oncol doi:10.1200/jco.2012.47.1102 (2013).
NEWS IN BRIEF
•	 Particulate Matter Air 
Pollution Raises European 
Lung Cancer Risk
European Study of Cohorts for Air Pollution Effects, one 
of the largest studies of its kind, showed that long-term 
exposure to particulate matter (PM2.5, with a diameter 
<2.5 μm and PM10, with a diameter <10 μm) increases 
the risk of lung cancer even at concentrations below 
the existing European Union air quality limit values for 
PM10 (40 μg/m3) and PM2.5 (25 μg/m3), according to 
data published in Lancet Oncology. This meta-analysis 
of 17 cohort studies in nine European countries included 
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PM2.5 pollution and by 22% for every increase of 10 µg/m3 of PM10 
pollution. This study, however, showed no association between lung 
cancer risk and nitrogen oxides or traffic intensity on the nearest street.
•	 FDA Approves Gilotrif  
for Late-Stage NSCLC
This approval is concurrent with a companion 
diagnostic, therascreen EGFR RGO PCR kit, which 
identifies the EGFR mutations. On the basis of the 
findings of the LUX-Lung 3 trial, which compared 
afatinib with cisplatin and pemetrexed in previously 
untreated EGFR-mutant non–small-cell lung cancer 
patients, afatinib demonstrated a superior response 
rate and progression-free survival, more favorable 
safety profile, and significantly better patient-reported 
outcomes compared with that of chemotherapy in this 
patient population.
approximately 313,000 people, of which 2095 developed lung cancer 
over a mean of 13 years of follow-up. The lung cancer risk (particularly 
adenocarcinomas) increased by 18% for every increase of 5 µg/m3 of 
Afatinib (Gilotrif, Boehringer Ingelheim) has been approved by 
the FDA for treatment of patients with metastatic non–small-cell 
lung cancer, harboring epidermal growth factor receptor (EGFR) 
mutations (exon 19 deletions or exon 21 L858R substitution). 
•	 Novel TKI AP26113 Shows 
Promise in ALK-Positive 
Patients
(69%), adverse events (23%), and death (8%). Nausea 
(45%), fatigue (39%), and diarrhea (27%) were the 
most common adverse events. The most common grade 
3/4 treatment-related adverse event was diarrhea (5%). 
Of the 44 patients enrolled, 21 were ALK-positive (18 
in NSCLC). In 56% of the 18 evaluable ALK-positive 
patients, responses were observed in patients untreated 
with or had one prior crizotinib (Xalkori; Pfizer) 
treatment, with 40 weeks being the longest response. 
Phase II trial is being planned in four patient cohorts: 
crizotinib-naive NSCLC, crizotinib-resistant NSCLC, 
epidermal growth factor receptor tyrosine kinase 
inhibitor–resistant NSCLC, and those with other tumors.
According to data presented at the WIN Symposium in Paris, the 
novel tyrosine kinase inhibitor AP26113 (Ariad Pharmaceuticals) 
shows encouraging antitumor activity and seems to be well-tolerated 
in patients with anaplastic lymphoma kinase (ALK)–positive 
malignancies. Initial activity in patients with epidermal growth 
factor receptor mutations was also demonstrated. This open-label, 
multicenter phase I/II study evaluated AP26113 in 44 patients enrolled, 
of which 37 had non–small-cell lung cancer (NSCLC). Twenty-six 
patients terminated the treatment because of disease progression 
